MedTrace Logo

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

NCT00243061 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-08-27

Study results available
· View outcomes & findings →

Summary

This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

Conditions

  • Acral Lentiginous Malignant Melanoma
  • Ciliary Body and Choroid Melanoma, Medium/Large Size
  • Ciliary Body and Choroid Melanoma, Small Size
  • Extraocular Extension Melanoma
  • Intraocular Melanoma
  • Iris Melanoma
  • Lentigo Maligna Malignant Melanoma
  • Recurrent Melanoma
  • Stage, Intraocular Melanoma
  • Stage IV Melanoma
  • Superficial Spreading Malignant Melanoma

Interventions

DRUG

cediranib maleate

Given orally

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Elaine McWhirter · Princess Margaret Hospital Phase 2 Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243061 on ClinicalTrials.gov